The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1625
Cabotegravir/Rilpivirine (Cabenuva) for HIV-1 Infection
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
The FDA has approved Cabenuva (ViiV Healthcare), an extended-release formulation of the new integrase strand transfer inhibitor (INSTI) cabotegravir copackaged with an extended-release formulation of the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine, as a once-monthly complete regimen for intramuscular (IM) treatment of adults with HIV-1 infection who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral (ARV) regimen, have no history of treatment failure, and have no known or suspected resistance to either drug. Oral cabotegravir (Vocabria) was also approved by the FDA for use in combination with oral rilpivirine (Edurant) as a daily one-month lead-in regimen before starting treatment with the monthly IM combination. Cabenuva is the first complete long-acting regimen to be approved by the FDA for treatment of HIV-1 infection. ... more
     
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Cabotegravir Rilpivirine (Cabenuva) for HIV-1 Infection
Article code: 1625b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian